Simple Laboratories LLC

Simple Laboratories LLC was paid $49.63M by Medicaid between Jan 2018 and Dec 2024, across 227 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 39% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Illinois

Rank by total paid#4 of 235

Median peer was paid$123K

This provider vs. median404×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	158,079	$1.85M
2019	238,847	$3.33M
2020	331,741	$8.05M
2021	533,733	$12.75M
2022	503,669	$12.87M
2023	272,289	$7.65M
2024incomplete	167,976	$3.12M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	39%	319,874	113,643	$19.54M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	11%	139,738	74,675	$5.45M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	7.7%	215,060	75,952	$3.85M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	5.1%	59,918	45,234	$2.53M
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	3.5%	94,403	26,657	$1.75M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	2.2%	9,680	4,470	$1.11M
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	2.2%	28,992	7,276	$1.09M
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.9%	17,743	15,442	$941K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	1.6%	21,880	17,954	$800K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.6%	21,766	17,974	$795K
80321		1.6%	20,223	9,234	$775K
84443	Thyroid stimulating hormone (TSH)	1.5%	57,269	52,177	$744K

215 more codes

80053	Comprehensive metabolic panel	1.4%	84,055	$681K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.1%	48,362	$524K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	1.0%	21,313	$515K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	85,927	$413K
80061	Lipid panel	<1%	73,599	$388K
82607		<1%	32,890	$337K
87481		<1%	7,620	$329K
83036	Hemoglobin; glycosylated (A1C)	<1%	54,013	$297K
80050	General health panel	<1%	16,920	$288K
80361		<1%	24,320	$253K
82746		<1%	23,882	$240K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	809	$226K
80348		<1%	23,028	$197K
83540		<1%	31,053	$166K
86480		<1%	3,501	$155K
86706		<1%	13,274	$155K
87511		<1%	4,172	$154K
86780		<1%	10,372	$147K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	8,885	$147K
80346		<1%	21,522	$144K
80324		<1%	20,980	$138K
80358		<1%	13,350	$136K
87086	Culture, bacterial; quantitative colony count, urine	<1%	16,489	$129K
86003		<1%	10,092	$125K
82728		<1%	17,934	$122K
86803		<1%	9,116	$113K
80353		<1%	12,844	$108K
80354		<1%	18,429	$103K
84466		<1%	13,533	$102K
80074		<1%	3,013	$99K
83735		<1%	17,664	$99K
86769		<1%	2,715	$95K
84153		<1%	8,112	$92K
80365		<1%	21,500	$84K
80356		<1%	23,988	$82K
83970		<1%	2,983	$79K
84439		<1%	11,701	$78K
80349		<1%	16,094	$72K
86696		<1%	4,205	$67K
87186		<1%	7,480	$66K
87340		<1%	7,009	$64K
84403		<1%	3,077	$64K
85027		<1%	12,129	$60K
81001		<1%	25,462	$59K
80048	Basic metabolic panel (calcium, ionized)	<1%	8,781	$56K
84550		<1%	18,374	$55K
87088		<1%	6,135	$55K
87641		<1%	1,668	$54K
84436		<1%	10,265	$54K
86695		<1%	4,320	$51K
83655		<1%	4,932	$51K
80359		<1%	3,707	$51K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	2,117	$48K
86140		<1%	11,444	$47K
82550		<1%	11,562	$45K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	823	$45K
80345		<1%	4,263	$45K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	1,269	$43K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	2,651	$41K
80373		<1%	9,450	$41K
86735		<1%	3,498	$40K
82533		<1%	3,421	$40K
84480		<1%	4,543	$39K
84100		<1%	12,312	$38K
80355		<1%	2,001	$37K
87581		<1%	1,054	$37K
87486		<1%	1,040	$36K
87653		<1%	1,074	$34K
87522	Neg quan hep c or qual rna	<1%	1,008	$33K
83615		<1%	8,883	$33K
84481		<1%	3,728	$33K
80360		<1%	10,391	$32K
86677		<1%	2,363	$31K
86762		<1%	4,018	$30K
86038		<1%	2,608	$29K
80366		<1%	1,630	$29K
81513		<1%	318	$29K
86705		<1%	2,631	$28K
84479		<1%	5,532	$28K
85651		<1%	7,503	$27K
80337		<1%	444	$27K
86765		<1%	3,501	$26K
82570		<1%	6,687	$26K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	2,304	$26K
82043		<1%	7,359	$25K
86694		<1%	2,481	$25K
87529		<1%	368	$24K
36415	Collection of venous blood by venipuncture	<1%	20,167	$23K
80369		<1%	430	$23K
86592		<1%	6,518	$22K
87563		<1%	985	$21K
87500		<1%	827	$21K
87070		<1%	3,794	$20K
82785		<1%	2,740	$19K
87640		<1%	542	$18K
80338		<1%	856	$17K
83001		<1%	1,072	$17K
83880		<1%	892	$16K
86709		<1%	3,226	$16K
86225		<1%	1,521	$15K
80076		<1%	2,694	$15K
80164		<1%	2,065	$15K
84146		<1%	1,282	$14K
80344		<1%	435	$13K
80370		<1%	981	$12K
83721		<1%	5,124	$12K
85610		<1%	3,676	$11K
80368		<1%	700	$10K
80362		<1%	1,070	$10K
86431		<1%	1,723	$10K
83002		<1%	1,075	$10K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	136	$9K
85045		<1%	4,072	$9K
87631		<1%	134	$9K
84681		<1%	727	$9K
82977		<1%	3,413	$9K
83090		<1%	719	$9K
83550		<1%	1,358	$8K
86258		<1%	580	$8K
80372		<1%	1,156	$8K
84702		<1%	1,058	$8K
86364		<1%	582	$8K
85660		<1%	1,939	$8K
82150		<1%	1,610	$8K
84703		<1%	1,344	$8K
86141		<1%	642	$7K
87498		<1%	188	$7K
80177		<1%	880	$7K
84270		<1%	481	$7K
82960		<1%	1,238	$6K
80342		<1%	208	$5K
82784		<1%	665	$5K
86704		<1%	621	$5K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	373	$5K
83690		<1%	881	$5K
84144		<1%	479	$4K
82670		<1%	346	$4K
83021		<1%	339	$4K
86800		<1%	343	$4K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	120	$4K
83992		<1%	204	$3K
82627		<1%	404	$3K
86376		<1%	321	$3K
G0471	Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)	<1%	3,100	$3K
84450		<1%	745	$3K
80185		<1%	240	$3K
86901		<1%	708	$3K
84145		<1%	154	$3K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	84	$2K
85730		<1%	552	$2K
86200		<1%	284	$2K
80202		<1%	202	$2K
84460		<1%	783	$2K
86787		<1%	153	$2K
84425		<1%	179	$2K
86900		<1%	674	$2K
80178		<1%	348	$2K
84134		<1%	180	$2K
86708		<1%	135	$2K
83516		<1%	59	$1K
80374		<1%	80	$1K
82140		<1%	164	$1K
87493		<1%	62	$1K
87040		<1%	115	$1K
87205		<1%	379	$1K
87536		<1%	16	$1K
82248		<1%	318	$1K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	17	$880.01
87634		<1%	52	$879.16
84132		<1%	228	$878.66
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	<1%	1,633	$860.57
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	72	$744.72
86060		<1%	99	$730.17
82747		<1%	57	$684.60
82947		<1%	221	$611.63
80069		<1%	89	$599.17
86593		<1%	147	$498.66
86317		<1%	45	$492.84
87390		<1%	21	$431.19
80156		<1%	53	$411.81
83520		<1%	36	$411.58
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	632	$390.80
87541		<1%	13	$381.60
82626		<1%	46	$364.60
84154		<1%	29	$309.69
84402		<1%	18	$295.36
87184		<1%	48	$284.91
82330		<1%	26	$272.59
84305		<1%	17	$227.87
87480		<1%	15	$221.77
87510		<1%	15	$221.77
82378		<1%	16	$216.99
86702		<1%	21	$191.13
86804		<1%	19	$186.85
87081		<1%	34	$175.79
85379		<1%	29	$171.62
87210		<1%	41	$167.41
86701		<1%	21	$166.65
87150		<1%	25	$151.30
82274		<1%	15	$144.21
80159		<1%	23	$137.89
87660		<1%	15	$134.82
87077		<1%	76	$128.26
83525		<1%	16	$123.77
85007		<1%	40	$122.79
81025		<1%	29	$96.31
82465		<1%	18	$50.73
84075		<1%	29	$37.44
80051		<1%	18	$22.21
82310		<1%	17	$11.12
82565		<1%	17	$11.00
82247		<1%	17	$10.80
82040		<1%	17	$10.68
84155		<1%	17	$7.88
80367		0%	42	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTIRADO, HILDA (SNR RCM BILLING MANAGER)